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Abstract
Background: High risk human papillomavirus (HR-HPV) infects mucosal surfaces and HR-HPV
infection is required for development of cervical cancer. Accordingly, enforced expression of the
early HR-HPV proteins can induce immortalisation of human cells. In most cervical cancers and
cervical cancer cell lines the HR-HPV double stranded DNA genome has been integrated into the
host cell genome.
Methods: We have used a retroviral GUS reporter system to generate pools of stably transfected
HaCaT and SiHa cells. The HPV-16 early sequences that are deleted upon integration of the HPV-
16 genome was inserted into the 3' UTR of the reporter mRNA. Pools containing thousands of
independent integrations were tested for the steady state levels of the reporter mRNA by Real
Time PCR and reporter protein by a GUS enzymatic activity assays. In addition, we tested the
cellular distribution and half lives of the reporter mRNAs. The integrity of the reporter mRNAs
were tested by northern blotting.
Results: We show that the 3' region of the HPV-16 early mRNAs (HPV-16 nucleotide (nt.) 2582–
4214) act in cis to decrease both mRNA and protein levels. This region seems to affect
transcription from the exogenous minimal CMV promoter or processing of the reporter mRNA.
The observed repression was most pronounced at the protein level, suggesting that this sequence
may also affect translation. For the HPV types: 2, 6, 11, 13, 18, 30, 31, and 35 we have investigated
the regulatory effect of the regions corresponding to the HPV-16 nt. 3358–4214. For all types,
except HPV-18, the region was found to repress expression by posttranscriptional mechanisms.
Conclusion: We find that the 3' region of HPV-16 early mRNAs interfere with gene expression.
It is therefore possible that the deletion of the 3' part of early HPV-16 mRNAs occurring during
cervical oncogenesis could contribute to transformation of cells through deregulation of the viral
oncogene synthesis. Moreover, we find that the corresponding region from several other HPV
types also repress expression, suggesting that the repression by this region may be a general feature
of the HPV life cycle.
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Background
Human Papillomaviruses (HPV) form a large family of
homologous circular double stranded DNA viruses that
infect the cutaneous and mucosal surfaces of humans.
Genital infections with HPV are sexually transmitted and
occur frequently in women. Although the majority of
infected women will clear the infection within a relatively
short time period, some develop a persistent infection
[1,2]. This initial clearance may depend on immunologi-
cal or non-immunological mechanisms [3]. The genital
HPV types can be divided into high and low risk types.
The high risk HPV (HR-HPV) types (16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68, 73, and 82) are classified as car-
cinogenic to humans [4], because epidemiological and
molecular studies have shown that infection with one of
these HR-HPV types is necessary, but not sufficient for
development of cervical cancer [5]. Only a small fraction
of persistent HR-HPV infections will progress to high
grade cervical lesions and cervical carcinoma. At the
molecular level the development of cervical cancer is
driven by enforced expression of two oncoproteins (E6
and E7) encoded by the HR-HPV types [6]. HR-HPV E6
and E7 target a large number of cellular proteins involved
in normal cellular regulation and in this way facilitate cel-
lular and viral DNA replication in differentiating post
mitotic keratinocytes [7,8]. This is crucial for amplifica-
tion of the viral genome and completion of the viral life-
cycle. In the normal viral lifecycle E6 and E7 are expressed
at low levels and preferably in the differentiating cells.
Probably the low expression of the viral genes helps the
virus to avoid detection by the host immune system. The
regulation of E6 and E7 expression is complex and occurs
on many levels. Interestingly, in most cervical cancers and
cervical cancer cell lines the HR-HPV double stranded
DNA genome has been integrated into the host cell
genome [9-12]. There seems to be little or no preference
for integration in specific genes, which suggests that inser-
tional mutagenesis generally is not involved in the gener-
ation of cervical cancer cells [13-15]. Conversely,
investigations have shown that in a high percentage of cer-
vical cancers and cell lines derived from cervical cancers
the circular viral genome has been linearized in the
sequence that encode the HPV E1 and E2 proteins before
integration (figure 1) [9,14,16,17]. These findings dem-
onstrate that integration in this exact region of the HPV
genome confers a selective advantage to cells during cervi-
cal oncogenesis and strongly suggest that this region could
be of major importance for regulation of the E6 and E7
oncogenes during the normal viral lifecycle. Many studies
have addressed the nature of this selective advantage, and
several different mechanisms appear to be involved. First,
breakage and integration of the HPV genome in E1 or E2
will eliminate expression of the viral proteins E1, E2, E5,
L1 and L2. The elimination of E2 expression is thought to
be of particular importance for malignant progression. It
has been shown that the HPV promoter region contains
four E2 binding sites and binding of HPV E2 proteins to
these sites repress viral transcription [18,19]. Therefore
abrogation of the E2 expression probably leads to
increased transcription of E6 and E7. Also, the HR-HPV E2
proteins can induce apoptosis independently of other
HPV proteins [20,21]. Furthermore, it is possible that the
loss of HPV protein expression facilitates evasion of the
immune system, because many women have immunore-
activity towards E2 epitopes that are conserved between
high and low risk HPV types [22]. Second, integration
may have a direct effect on transcription from the HPV
promoter. It is possible that regulatory elements present
in the cellular sequence adjacent to the integrated viral
sequence stimulate transcription from the viral promoter.
Also several Matrix Attachment Regions (MARs) are
present in the HPV-16 genome and it has been found that
the HPV-16 MARs repress transcription from a reporter
construct when in the episomal form. However, when an
identical construct was stably integrated into the cellular
genome the same regions were found to stimulate tran-
scription [23]. Third, as a consequence of integration the
3' part of the HPV mRNA will be deleted and replaced
with sequences derived from the host cell (see figure 1).
Thus, in these cells E6 and E7 will be expressed from a chi-
meric HPV/cellular mRNA. It has been shown that such
chimeric mRNAs are present at higher steady state levels
than the normal HPV mRNAs [17]. Expression of the E6
and E7 oncogenes from the integrated HPV genome
requires that a polyadenylation signal located in the host
cell DNA is used for processing of the chimeric mRNA.
Investigations have shown that the HPV-31 polyadenyla-
tion signal functions quite inefficiently [24] and usage of
an efficient cellular polyadenylation signal may therefore
enhance the expression of the E6 and E7 oncogenes.
Another possibility is that the stability or the translation
of the chimeric mRNA is enhanced compared to the nor-
mal HPV mRNA. It has been demonstrated that the A/U
rich 4005–4213 region from HPV-16 decreased the half-
life of a reporter messenger, when inserted downstream of
β-globin reporter construct [17]. In another study the
same region was shown to decrease the steady state level
of the early HPV mRNA by 1.6 fold [25]. This indicates
that the expression of E6 and E7 may be enhanced
through the deletion of the U rich region.
All HPV-16 mRNAs that encode E6 and E7 contain the
sequence from the splice acceptor located at nt. 3358 to
the early polyadenylation signal located at nt. 4215 and
this sequence may be involved in regulation of the HPV-
16 E6 and E7 expression in the normal HPV life cycle. Fur-
thermore, the large majority of chimeric mRNAs created
by integration of the HPV-16 genome in cervical cancer
cells are spliced from the 880 splice donor located shortly
downstream of the E7 reading frame to a cellular spliceBMC Infectious Diseases 2005, 5:83 http://www.biomedcentral.com/1471-2334/5/83
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acceptor (figure 1) [14]. Thus, the elimination of the HPV-
16 sequence from nt. 3358–4214 may also be important
for regulation of E6 and E7 during the normal HPV-16
lifecycle and could contribute to selection of cells contain-
ing integrated HPV-16 genomes during cervical oncogen-
esis. Here, we demonstrate that the HPV sequence
downstream of the HPV-16 nt. 2582 and 3358 splicesites
decrease mRNA steady state level and may also affect
mRNA translation. Homologous sequences from other
HPV types were also found to decrease gene expression.
Methods
Cloning of reporter construct
The HRSp-GUS retroviral reporter vector [26,27] was gen-
erously provided by professor Helen Blau, Stanford Uni-
versity School of Medicine, California. HPV sequences
were PCR-amplified from plasmid templates (pBR322-
HPV-2, pSV010-HPV-6, pBR322-HPV-11, pBR322-HPV-
13, pBR322-HPV-16, pBR322-HPV-18, pBR322-HPV-30,
pBR322-HPV-31 and pBR322-HPV-35 (short BamHI frag-
ment)) with pfu polymerase (Promega) and primers from
MWG Biotech, Ebersberg, Germany. The following
regions were amplified : HPV16: 2582–4214, 3358–4214,
4063–4214, 4063–4310, HPV-18: 3378–4234, HPV-31:
3295–4137, HPV-6: 3325–4377, HPV-11: 3325–4370,
HPV-35: 3301–4158, HPV-2: 3299–4387, HPV-13: 3332–
4331, HPV-30: 3206–4216. Primers included restriction
sites for cloning into Apa I / PinA I digested pHRSp-GUS
or into Xho I / PinA I digested pHRSp-GUS (HPV-16 nt.
4063–4310). Plasmid DNA for transfection was prepared
with Qiagen kits and all inserts were sequenced.
Cell culture and retroviral infections
The SiHa cell line was obtained from American Type Cul-
ture Collection (ATCC number HTB-35) and professor
Norbert Fusenig, DKFZ, Heidelberg, kindly provided the
HaCaT cell line. The PG13 amphotropic packaging cell
line was a gift from PhD Lene Pedersen, Aarhus Univer-
sity, Denmark. 8,6 cm dishes with PG13 cells (grown in
10% neonatal calf serum) were transfected with pHRSp-
GUS reporter constructs using the LipofectaminePLUS
reagent (Invitrogen). 72 hours post transfection Puromy-
cin (Sigma P7255) was added to a final concentration of
2,5 µg/ml for selection of stably transfected cells. The cells
were transferred to T175 flasks that were allowed to grow
to confluence. Viral supernatants were harvested by
changing the media to 10 % Foetal calf serum (Invitro-
gen) and incubating the cells for 24 hours at 32°C, 5%
CO2. The supernatants were filtered through a 0,45 µm
syringe filter (Satorius) and Polybrene was added to a
final concentration of 8 µg/ml. For each construct three
8.6 cm dishes of HaCaT or SiHa were each infected 4
hours with 4 ml of viral supernatant. 72 hours after trans-
duction the infected cells were selected by adding 2,5 µg/
ml Puromycin (Sigma P7255) to the cell media. The
number of colonies was evaluated for each infection
(pool), so that at least 1000 different colonies were
present in each pool. For each construct three independ-
ent infections were performed.
Quantification of mRNA levels by Real time RT-PCR
1 × 106 HaCaT or SiHa cells from the different cell pools
(three for each construct) were plated in 8.6 cm cell cul-
ture dishes and after 48 hours total RNA was isolated with
the Qiagen RNeasy kit according to the instructions of the
manufacturer. 10 µg RNA were treated with Amplification
grade RNase free DNase I (Invitrogen). Real Time PCR
reactions were run on a MJ Research DNA Engine Opti-
con™. Primers pairs specific for the GUS (5'-GTGATGA-
TAATCGGCTGATG-3' and 5'-
CCTGCGTCAATGTAATGTTC-3') and PURO (5'-
AGGGCAAGGGTCTGGGCA-3' and 5'-TCGGCGGT-
HPV-16 integrations during oncogenesis Figure 1
HPV-16 integrations during oncogenesis. In normal 
HPV-16 infections the HPV-16 genome is present as an epi-
some. The mRNAs that encode the HPV-16 E6 and E7 onco-
genes are transcribed by the main promoter, spliced from 
the 880 splice donor and uses the early polyadenylation sig-
nal. During cervical oncogenesis the HPV-16 genome is inte-
grated into the cellular genome. This integration occurs in 
the E1/E2 region and leads to generation of chimeric mRNAs 
that encode E6 and E7. Most often the chimeric mRNAs are 
of the A type that are spliced to a cellular splice acceptor 
[14].BMC Infectious Diseases 2005, 5:83 http://www.biomedcentral.com/1471-2334/5/83
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GACGGTGAAG-3') coding sequences were designed. The
GUS primer set was used with an annealing temperature
of 58°C and the PURO primer set with an annealing tem-
perature at 63°C. The QuantiTect SYBR Green RT-PCR Kit
from Qiagen was used to assemble 25 µl RT-PCR/PCR
reactions in triplicate. The following PCR profile was
used: 30 min. at 50°C, 15 min. at 95°C, (15 s at 94°C, 30
s at 58 or 63°C, 1 min at 72°C) × 40 followed by record-
ing of a melting curve. The threshold cycle Ct for individ-
ual reactions was determined with the Opticon software.
All templates were checked for DNA contamination by
omitting the reverse transcriptase in control reactions. The
GUS mRNA level relative to the PURO mRNA level for
each construct was calculated with the 2-∆∆Ct method and
expressed relative to the empty vector [28]. The GUS
mRNA levels were normalized to the PURO mRNA levels
to ensure that differences between constructs in the effi-
ciency of retroviral infection does not influence the results
[27]. ∆Ct values for individual pools were calculated and
the ∆Ct average for the empty vector was treated as an arbi-
trary constant and used to calculate ∆∆Ct values for all
pools. The mRNA levels for individual pools were calcu-
lated by evaluating the 2-∆∆Ct term. The results for the three
independent pools for each construct were averaged and
the standard error of the mean was calculated. For mRNA
half-life experiments Actinomycin D (Sigma A9415) was
added to the medium to a concentration of 2 µg/ml and
total RNA was harvested from the cells at t = 0, 1, 3, 6, 9,
15 hrs. Aliquots containing equal amounts of total RNA
were used as templates for Real Time PCR analysis with
the GUS specific primerset. The GUS mRNA levels for each
timepoint were calculated from the Ct values, averaged
and expressed relative to the mRNA level at the time of
Actinomycin D addition. For examination of nuclear/
cytoplasmic mRNA ratios SiHa cells were trypsinised and
2 × 106 cells were used for preparation of cytoplasmic RNA
with the RNeasy kit from Qiagen. The nuclear pellets were
washed three times in RLN buffer (Qiagen) and used for
isolation of nuclear RNA with the Qiagen RNeasy proce-
dure for total RNA. The mRNA levels were determined
with Real time PCR. The GAPDH mRNA was detected
with the following primer set (5'-GAAGGTGAAGGTCG-
GAGTC-3') and (5'-GAAGATGGTGATGGGATTTC-3').
Northern blot analysis
Total RNA (app. 7,5 µg) from the SiHa cell pools stably
transfected with the different constructs was separated on
a MOPS 1% agarose gel, transferred to a BrightStar Mem-
brane (Ambion) and crosslinked with the autocrosslink
setting in a Stratalinker (Stratagene) according to the rec-
ommendations in the NorthernMax kit from Ambion. Nt.
6–131 and nt. 538–1037 of the GUS reporter mRNA were
cloned into pBluescript II SK (+) and used for preparation
of radioactively labelled probes by in vitro transcription
with Radioactive labelled UTP [α-32P, 800 Ci/mmol] and
the T7 Maxiscript kit (Ambion) according to the recom-
mendations of supplier. The crosslinked membrane was
hybridised over night with 1 × 106 cpm probe per ml of
ULTRAhyp solution at 72°C and washed the following
day according to the instructions in the NorthernMax pro-
tocol. Finally, the membrane was exposed to Biomax MR
film (Kodax) for 72 hours at 4°C.
Quantification of total protein and GUS protein
1 × 106 HaCaT or SiHa cells from the different cell pools
(three for each construct) were plated in 8.6 cm cell cul-
ture dishes. After 48 hours cells were scraped in lysis
buffer: 100 mM potassiumphosphate (pH 7.8) and 0.2 %
Triton X-100 with DTT added to 0,5 mM immediately
before use. Membrane debris was pelleted by centrifuga-
tion (15000 g, 4°C) for 3 min. and the supernatant was
collected and stored at -80°C. The Coomassie®Plus Rea-
gent (PIERCE) was used to determine the total protein
concentration of the extracts. The level of GUS protein in
the extracts was determined with the FluorAceTM β-glu-
curonidase Reporter Assay kit from BIORAD. All cell
extracts were diluted 1:10, 1:100, 1:1000 or 1:10000 to
ensure that the measurements were within the linear
range of the assay. Fluorescence was counted on a Wallac
VICTOR2 Multilabel Counter. The GUS protein levels
were normalized with the total protein levels and
expressed relative to the HRSp-GUS vector. For each con-
struct the three independent pools were averaged and the
standard error of the mean was calculated. Translational
was evaluated for the different constructs by normalizing
the GUS protein levels with the total levels of the GUS
mRNA (not normalized to PURO) as determined by Real
Time RT-PCR.
Results
We have investigated the effect of posttranscriptional reg-
ulation, including translation, on the expression of the
HPV-16 early genes with the HRSp-GUS vector that has
been designed for investigation of the regulatory proper-
ties of UTR sequences [26,27] (see figure 2a). The main
advantage of this vector is that the reporter mRNAs are
expressed at low levels from one or a few retroviral inte-
grations. Expression from integrated reporter constructs is
a good model for the integrated oncogenic HPV DNA that
is found in advanced cervical lesions and furthermore the
low expression ensures that transacting factors are not
titrated out. In the reporter vector we have inserted differ-
ent HPV-16 sequences 3' to the GUS coding sequence to
determine how they influence the steady state level of the
reporter mRNA and reporter protein (figure 2a). All steady
state levels were determined as the average of data col-
lected from three independent cell pools each containing
several thousand clones of stably transfected SiHa and
HaCaT cells. Total RNA from different clones was used for
Northern Blot analysis with two probes specific for theBMC Infectious Diseases 2005, 5:83 http://www.biomedcentral.com/1471-2334/5/83
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Effects of HPV-16 sequences on the steady state level of GUS mRNA and GUS protein Figure 2
Effects of HPV-16 sequences on the steady state level of GUS mRNA and GUS protein. a) Schematic representa-
tion of the HRSp-GUS retroviral reporter vector [26,27] and the location of the GUS northern probes and the Real Time PCR 
amplicon. b) Northern Blot analysis of mRNA from SiHa cell pools (only GUS probe 1 experiment is shown). Blotting of 
mRNA from the HaCaT cell pools is not shown, but yielded similar results. c) GUS mRNA steady state levels. For each con-
struct the steady state levels of the GUS mRNA and PURO mRNA were determined with real-time RT-PCR. The GUS mRNA 
levels were normalized with the PURO mRNA. The data plotted is the average of results from three independent pools of 
infected SiHa or HaCaT cells expressed relative to the empty HRSp-GUS construct. The error bars indicate the standard error 
of the mean. d) Reporter protein produced per reporter mRNA. For each construct the steady state GUS activity and total 
protein levels were determined. The GUS activities were normalized with the total protein levels. Protein/RNA ratios of the 
different reporter mRNA was evaluated by calculation of the ratio between the steady state levels of GUS protein to GUS 
mRNAs (not normalized for PURO) The data plotted is the average of results from three independent pools of infected SiHa 
or HaCaT cells expressed relative to the empty HRSp-GUS construct. The error bars indicate the standard error of the mean. 
e) Cellular distribution of Reporter mRNAs. The ratio of cytoplasmic to nuclear RNA for the GUS mRNA (left), PURO mRNA 
(middle) and GAPDH mRNA (right) in the different reporter cell lines.BMC Infectious Diseases 2005, 5:83 http://www.biomedcentral.com/1471-2334/5/83
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GUS sequence. One of these probes anneals to the first
120 bases of the reporter mRNA to ensure that all spliced
reporter as well as the full-length mRNAs would be
detected. The probes only detected the expected full-
length mRNAs and no shorter spliced forms. For the nt.
2582–4214 reporter construct no mRNA was detectable
(figure 2b). We find that the inclusion of the A/U rich
HPV-16 sequence from nt. 4063 to 4214 in the reporter
construct has little inhibitory effect on steady state level of
the reporter mRNA (figure 2c). In the SiHa cell line the
reporter mRNA is expressed to app. 90 % of the level of
the empty vector, whereas the HPV sequence seems to
have a stabilizing effect in the HaCaT cell line, although
we have large differences between our pools for this
reporter construct. The region from the HPV-16 nt. 3358
splice acceptor to the early polyadenylation signal is
present in all HPV-16 mRNAs that encode E6 and E7. We
find that HPV-16 nt. 3358–4214 region shows a signifi-
cant repression of the steady state level mRNA both in the
SiHa and HaCaT cell line when inserted into the HRSp-
GUS vector (figure 2b). The HPV-16 genome also contains
splice acceptors at nucleotides 2582 and 2709 and we
therefore investigated the steady state level of a construct
with the HPV-16 nt. 2582–4214 sequence inserted. In the
SiHa cell line this construct further decreased the steady
state level of the reporter mRNA and in the HaCaT cell line
only extremely low levels of GUS mRNA were detected
(figure 2b and 2c).
It has previously been demonstrated that the HPV-31
early polyadenylation signal functions inefficiently [24]
and we therefore made a construct with the HPV-16 early
polyadenylation region included instead of the bovine
Growth Hormone (bGH) polyA region present in the
HRSp-GUS vector (figure 2a). In our experiments usage of
the HPV-16 early polyadenylation signal (HPV-16 nt.
4063–4310) does not significantly reduce the steady state
levels of the reporter mRNA compared to the similar con-
struct containing the bGH polyadenylation region (HPV-
16 nt. 4063–4214) (figure 2b). This indicates that in SiHa
and HaCaT keratinocytes the HPV-16 early polyadenyla-
tion signal functions reasonably efficiently.
Although it is quite possible that the expression of the
HPV-16 E6 and E7 proteins is regulated at the protein
level by the sequences downstream of the reading frames,
this has to our knowledge never been investigated in any
detail. We determined the steady state levels of the GUS
reporter protein normalized to total protein levels for the
different constructs. The normalized protein levels reflect
the full regulatory influence of the inserted sequences,
including effects on mRNA processing, mRNA transport,
mRNA stability and translation. To assess the influence
that the inserted HPV sequences have on the amount of
protein produced per mRNA we calculated the ratio
between the steady state levels of GUS protein (normal-
ized to total protein) and the steady state levels of the GUS
mRNA (normalized to total RNA)(figure 2d). This nor-
malization reveals that in neither cell line the HPV-16 nt.
4063–4214 region changes the protein/mRNA ratio,
whereas the HPV-16 nt. 2582–4214 region greatly reduces
the protein/mRNA ratio. The HPV-16 nt. 3358–4214
region significantly reduces the protein/mRNA ratio in the
SiHa cell line, but not in HaCaT cells. Inclusion of the
HPV-16 polyadenylation region instead of the bGH poly-
adenylation region in the HPV-16 4063–4310 construct
should give mRNAs with native HPV-16 3' ends. Com-
pared with the similar mRNA that contains the bGH poly-
adenylation region (HPV-16 nt. 4063–4214), this mRNA
produces less protein in the HaCaT cell line, whereas no
significant difference is present in SiHa cells (figure 2d).
Only the cytoplasmic pool of mRNA is available for trans-
lation and it is therefore possible that the reduction in
protein/mRNA ratio that we observe is caused by an
altered distribution of the reporter mRNAs. We therefore
isolated cytoplasmic and nuclear mRNA fractions and
determined the mRNA concentrations by real time PCR.
None of the inserted HPV-16 sequences affect the distri-
bution of the GUS reporter mRNA or the PURO and
GAPDH controls (figure 2e).
The effects that we observe on mRNA steady state levels
for the nt. 3358–4214 and 2583–4214 constructs could
be the result of decreased stability of the reporter mRNAs
or decreased transcription. To differentiate between these
two possible mechanisms, we determined the half-lives of
the two reporter mRNAs (figure 3b). The nt. 3358–4214
and 2583–4214 reporter mRNAs did not have signifi-
cantly lower half-life than the nt. 4063–4214 and control
mRNAs, which indicates the reduced steady state level is
caused by inhibition of transcription.
The genomic organisation of the different HPV types is
highly conserved. They all have two polyadenylation sig-
nals that divide the genome into an early and a late region.
Moreover all HPV types express E6 an E7 from mRNAs
that are spliced to a splice acceptor in the E2 reading frame
analogous to the HPV-16 nt. 3358 splice acceptor. We
therefore decided to determine if the negative effect on
translation that we observe with the HPV16 nt. 3358–
4214 region is a general regulatory feature of different
HPV types. The region from the E2 splice acceptor to the
early polyadenylation signal from HPV types: 2, 6, 11, 13,
16, 18, 30, 31 and 35 was therefore cloned into the 3' UTR
of the pHRSp-GUS vector and the steady state level of
reporter mRNA and protein was determined after trans-
duction of SiHa cells (figure 4a). To ensure that the
reporter constructs expressed the correct reporter mRNA
we performed a Northern Blot analysis with both the
probes shown in figure 2a. All pools expressed GUSBMC Infectious Diseases 2005, 5:83 http://www.biomedcentral.com/1471-2334/5/83
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mRNAs of the expected length (figure 4b), except for the
HPV-18 construct that expressed an additional, shorter
GUS mRNA of unknown structure. We find that all the
tested HPV sequences, except the ones derived from 18
and 31, decrease the steady state level of the reporter
mRNA compared to the empty vector (figure 4c). The larg-
est repression was observed with the HPV-2 construct. For
all types except HPV-35 and HPV-18 the repressive effect
of the inserted HPV sequence also decreased the transla-
tion (figure 4d). These results therefore indicate that the
Decay of reporter mRNAs Figure 3
Decay of reporter mRNAs. SiHa cells expressing the indicated constructs were treated with Actinomycin D to inhibit tran-
scription. mRNA levels of the different GUS reporter mRNAs normalized to total RNA was determined with real-time RT-
PCR at the indicated time points. At least three different measurements were made for each timepoint and the data plotted is 
the average relative to the mRNA level at the time of Actinomycin D addition. The error bars indicate the standard deviation.BMC Infectious Diseases 2005, 5:83 http://www.biomedcentral.com/1471-2334/5/83
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Effects of HPV 3' early regions on the steady state level of GUS mRNA and GUS protein Figure 4
Effects of HPV 3' early regions on the steady state level of GUS mRNA and GUS protein. a) Schematic represen-
tation of the HPV sequences that were cloned into the retroviral HRSp-GUS reporter vector [26,27]. b) Northern Blot analy-
sis of mRNA from SiHa cell pools (only GUS probe 1 experiments shown). c) GUS mRNA steady state levels. For each 
construct the steady state levels of the GUS mRNA and PURO mRNA were determined with real-time RT-PCR. The GUS 
mRNA levels were normalized with the PURO mRNA. The data plotted is the average of results from three independent pools 
of infected SiHa cells expressed relative to the empty HRSp-GUS construct. The error bars indicate the standard error of the 
mean. d) Protein produced per reporter mRNA For each construct the steady state GUS activity and total protein levels were 
determined. The GUS activities were normalized with the total protein levels. The protein/RNA ratios of the different 
reporter mRNA was evaluated by calculation of the ratio between the steady state levels of GUS protein to GUS mRNAs (not 
normalized for PURO). The data plotted is the average of results from three independent pools of infected SiHa cells 
expressed relative to the empty HRSp-GUS construct. The error bars indicate the standard error of the mean.BMC Infectious Diseases 2005, 5:83 http://www.biomedcentral.com/1471-2334/5/83
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posttranscriptional repression of the region from the E2
splice site to the early polyadenylation signal is a general
feature of different HPV types.
Discussion
In this study we have investigated if the HPV-16 early
genes are regulated at the posttranscriptional level. We
find that the HPV-16 nt. 2582–4214 region very effi-
ciently reduce the steady state level of a reporter mRNA
and the amount of protein that is produced from the
mRNA when compared to the empty reporter vector
HRSp-GUS vector (see figure 2). Moreover, a truncated
construct containing the HPV-16 nt. 3358–4214 region
also decreased the steady state level of reporter mRNA and
in one of the two cell lines tested reduced the protein/
mRNA ratio. In contrast the HPV-16 nt. 4063–4214
region encompassing the short U rich HPV-16 early 3'
UTR only, did not affect expression. The reporter assay
that we have used in our experiments is based on observa-
tion of steady state levels of the different reporter mRNAs
and of reporter protein. It is possible that splice acceptors
present in the inserted sequences could stimulate splicing
from cryptic splice donors in the reporter sequence and
this would make our results very difficult to evaluate. For
that reason we used Northern Blot analysis to confirm
that all the reporter mRNAs have the expected unspliced
structure. All constructs, except the HPV-18 construct, pro-
duced only the expected full length unspliced reporter
mRNA (figure 2b and 4b). The 2582–4214 construct did
not express sufficient amounts of reporter mRNA (full
length or spliced) to be detected by Northern Blot. Thus,
the lowered steady state levels of reporter mRNA that we
observe could reflect a decrease in reporter mRNA half-
life, a decreased rate of transcription or inhibition of
export of mRNA. Surprisingly, we found that none of our
reporter mRNAs containing HPV-16 sequence had a
decreased half-life (see figure 3). This indicates that the
inserted HPV-16 sequence influence the transcription
from the minimal CMV promoter included in the pHRSp-
GUS vector or affect the nuclear export of the mRNAs. It is
known that HPV-16 E5 region contain a strong matrix
attachment region [23,29] and it is possible that this
region or other unidentified enhancer elements influence
the CMV promoter. Moreover, it is well established that
the late mRNAs from several different papillomavirus
types contain sequences that interfere with mRNA export
[30-33]. Often these sequences bind factors involved in
splicing such as U2AF65 [32] and the U1 snRNA [30]. The
HPV-16 nt. 3358–4214 and 2582–4214 regions both con-
tain a splice donor located at HPV-16 nt. 3632 and the
HPV-16 nt. 2582–4214 region also contain the splice
acceptor at HPV-16 nt. 3358. Both these splice sequences
diverge from the consensus sequences, but are used dur-
ing the viral lifecycle and could therefore potentially con-
tribute to the repression that we observe by inhibiting
mRNA export and mediation of rapid degradation within
the nucleus. Still, we investigated the distribution of the
different reporter mRNA (figure 2e) and found that the
HPV-16 sequences does not change the distribution of the
reporter mRNAs. This suggests that the decrease in steady
state mRNA levels is caused by inhibition of the minimal
CMV promoter. Alternatively ineffective mRNA process-
ing of the reporter constructs may lead to very rapid
degradation (cotranscriptional) of the reporter mRNA
that cannot be detected in our RNA half-life experiments.
Jeon and Lambert have previously reported that the very
A/U rich 4005–4213 region from HPV-16 very efficiently
decreases the stability of a reporter mRNA [17]. The 3'
UTRs from short-lived mRNAs often contain destabilizing
A/U-rich elements (ARE) [34], but the HPV-16 A/U rich
sequence does not contain any of the canonical ARE
sequences (AUUUA). AREs and a few other RNA
sequences have been found to be highly overrepresented
in mRNAs with high turnover rate, but they are not strong
predictors of the mRNA turnover rate [35], This empha-
sizes that the ability of a RNA sequences to destabilize
mRNAs is highly context dependent and requires cooper-
ative binding of several factors. In our experiments the
HPV-16 sequence from nt. 4063–4214 does not influence
the steady state level or decrease the half-life of the
reporter mRNA (figure 2a and 3). Schwartz and coworkers
did not find any repressive effect of the HPV-16 nt. 4005–
4213 region on protein expression in their reporter system
[36] and weak inhibitory effect (1.6 fold inhibition) on
the mRNA level [25]. It is possible that the upstream nt.
4005–4063 sequence is necessary for the repression
observed by Jeon and Lambert and Schwartz and cowork-
ers. Another possibility is that the reporter systems and
cell lines used in the different studies influence the regu-
latory properties of this HPV-16 region.
It has been reported that the early polyadenylation region
from HPV-31 is app. 20 fold less efficient than the SV-40
late polyadenylation region and that this difference could
be reduced to a 5 fold difference by introduction of an effi-
cient binding site for the cleavage stimulatory factor CstF-
64 to the HPV-31 polyadenylation region [24]. Our exper-
iments indicate that the efficiency of the HPV-16 early
polyadenylation region from nt. 4215 to 4310 is compa-
rable with the efficiency of the bGH polyadenylation
region present in the HRSp-GUS vector (compare 4063–
4214 with 4063–4310, figure 2c). Clearly, these findings
may reflect a difference in the efficiency of the HPV-16
and HPV-31 early polyadenylation regions or the effi-
ciency of the bGH and SV40 polyadenylation regions.
Interestingly, Schwartz and coworkers have recently
shown that the U-rich sequence present in the HPV-16 3'
UTR enhances polyadenylation from the early HPV-16
polyadenylation signal [25]. The HPV-31 early 3' UTR isBMC Infectious Diseases 2005, 5:83 http://www.biomedcentral.com/1471-2334/5/83
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less U-rich than the HPV-16 early 3' UTR and may there-
fore not enhance polyadenylation in the same way. Still,
different cells and reporter systems were used in the differ-
ent studies.
In addition to decreased reporter mRNA steady state levels
we also observe that the mRNAs containing the HPV-16
nt. 2582–4214 and nt. 3358–4214 sequences produce
less protein per mRNA than the control mRNA. Only cyto-
plasmic mRNA is available for translation and since we
have measured total mRNA concentration, inhibition of
mRNA export and accumulation of reporter mRNAs in the
nucleus would result in a decreased protein/mRNA ratio
in our experiments. We find that the ratio of nuclear to
cytoplasmic mRNA is unaltered by the HPV-16 sequences
(figure 2e), which indicates that the inserted HPV
sequences may influence translation.
A productive HR-HPV infection relies on carefully regu-
lated expression of the HPV gene products. The expression
is coupled to the differentiation of the infected cells, so
that the viral proteins are expressed at low levels in the
basal and suprabasal cell layers, but are expressed at
higher levels in the more superficial cells that have exited
the cell cycle [37,38]. This strategy most likely helps to
keep the HPV infection hidden for the immune system.
The repression that we observe by the HPV-16 nt. 3358–
4214 and nt. 2582–4214 regions shows that HPV-16
exploits posttranscriptional mechanisms probably to keep
the expression of the E6 and E7 proteins at a suitably low
level. This is analogous to the repression of the late struc-
tural proteins of HPV-16, which also partly occur on the
level of mRNA processing, export, stability and translation
[30-32,39,40].
We next wondered if posttranscriptional repression could
be a general feature of early mRNAs from different HR-
HPV types and possibly all HPV types. The HPV types
tested include the high risk types HPV-16, HPV-18, HPV-
31, and HPV-35 and also the low risk types HPV-6, HPV-
11 and HPV-13, which frequently infect the genital tract
and cause condylomata acuminata, but are practically
absent in high grade lesions and in cervical cancers. In
addition, we have tested HPV-2, a benign HPV type with
a preference for cutaneous tissue and HPV-30, which is a
rather rare HPV type occasionally present in genital infec-
tions. We found that the region from the E2 splice accep-
tor to the early polyadenylation signal from all the tested
types except HPV-18 repress expression of the reporter by
decreasing mRNA steady state levels or reducing the
amount of protein produced or both (figure 4). Like the
HPV-16 sequence these HPV sequences therefore contain
elements that interfere with transcription and/or process-
ing of the mRNAs to reduce the steady state level of the
reporter mRNAs. Moreover, most of them also reduce
translation and it is therefore very likely that repression by
this region of the HPV genomes in a general feature of the
HPV life cycle. The HPV-18 sequence seems to increase
expression of the reporter through increased mRNA
steady state level and enhanced protein production, but
since we find that the HPV-18 construct in addition to the
expected full length reporter mRNA also express a shorter
mRNA this may be the reason for the increased expres-
sion. The finding that the 3' end of most HPV E6 and E7
mRNAs repress expression by posttranscriptional mecha-
nisms is interesting, since it suggests that posttranscrip-
tional repression of the early HPV genes may be a general
feature of many HPV types and possibly has evolved to
facilitate evasion of the host immune system. Still all the
HPV types tested are part of the A supergroup and more
distantly related types could be regulated very differently.
Conclusion
In conclusion, we demonstrate that the HPV-16 nt. 2582–
4063 region represses expression at the mRNA and possi-
bly also the protein level. This regulation could be
involved in the regulation of the HPV-16 E6 and E7 onco-
genes during the normal HPV lifecycle. Also for the HPV
types 2, 6, 11, 13, 16, 30, 31, 32 and 35 the region from
the E2 splice acceptor to the early polyadenylation signal
represses expression of the reporter construct. This indi-
cates that regions downstream of these splicesites func-
tion in the HPV lifecycle to repress the expression of the
early HPV proteins including the E6 and E7 oncoproteins.
For the HR-HPV types deletion of this region through
genomic integration occurring in the E1 or E2 open read-
ing frames could contribute to enhanced expression of E6
and E7 and increase the oncogenic potential of the
infected cells during cervical oncogenesis.
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